首页> 美国卫生研究院文献>NPG Open Access >Relationship between initial PSA density with future PSA kinetics and repeat biopsies in men with prostate cancer on active surveillance
【2h】

Relationship between initial PSA density with future PSA kinetics and repeat biopsies in men with prostate cancer on active surveillance

机译:主动监测男性前列腺癌的初始PSA密度与未来PSA动力学和重复活检之间的关系

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The objective of our study is to examine the correlation between PSA density (PSAd) at the time of diagnosis with PSA velocity (PSAV), PSA doubling time and tumour progression, on repeat biopsy, in men with prostate cancer on active surveillance. Data from 102 patients with clinically localized prostate cancer on active surveillance in the period between 1992 and 2007, who had the necessary parameters available, were collected. PSAd was calculated and correlated with PSAV, PSA doubling time (PSADT), Gleason score at diagnosis and local progression on repeated biopsies. PSAV was 0.64 and 1.31 ng ml–1 per year (P=0.02), PSADT of 192 and 113 months (P=0.4) for PSAd below and above 0.15, respectively. The rate of detecting high Gleason score (⩾7) at diagnosis was 6 and 23% for PSAd below and above 0.15, respectively. A total of 101 patients underwent at least a second biopsy and the incidence of upgrading was 10 and 31% for PSAd below and above 0.15, respectively (P=0.001). Although low PSAd is an accepted measure for suggesting insignificant prostate cancer, our study expands its role to indicate that PSAd <0.15 may be an additional clinical parameter that may suggest indolent disease, as measured by future PSAV and repeat biopsy over time.
机译:我们研究的目的是在进行定期活检的男性进行主动活检时,检查诊断时PSA密度(PSAd)与PSA速度(PSAV),PSA倍增时间和肿瘤进展之间的相关性。收集了1992年至2007年期间接受主动监测的102例临床局限性前列腺癌患者的数据,这些数据具有必要的可用参数。计算PSAd并将其与PSAV,PSA加倍时间(PSADT),诊断时的Gleason评分以及重复活检的局部进展相关联。每年PSAV分别为0.64和1.31ngngml –1 (P = 0.02),PSAd分别为0.15和高于0.15的PSADT为192和113个月(P = 0.4)。 PSAd低于0.15和高于0.15时,诊断时检出高Gleason评分(⩾7)的比率分别为6%和23%。总共101例患者至少接受了第二次活检,PSAd分别低于0.15和高于0.15的发生率分别为10%和31%(P = 0.001)。尽管低PSAd是暗示微不足道的前列腺癌的公认方法,但我们的研究扩大了其作用,以表明PSAd <0.15可能是可能暗示轻度疾病的其他临床参数,如未来PSAV和随时间反复进行活检所测。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号